Department of Bioengineering, University of California, Berkeley, CA, 94720, USA.
Department of Medicine, Cardiovascular Research Institute and Institute for Regeneration Medicine, University of California, San Francisco, CA, 94143, USA.
Adv Healthc Mater. 2020 Jan;9(2):e1900544. doi: 10.1002/adhm.201900544. Epub 2019 Nov 28.
Ischemic heart disease represents the leading cause of death worldwide. Heart failure following myocardial infarction (MI) is associated with severe fibrosis formation and cardiac remodeling. Recently, injectable hydrogels have emerged as a promising approach to repair the infarcted heart and improve heart function through minimally invasive administration. Here, a novel injectable human amniotic membrane (hAM) matrix is developed to enhance cardiac regeneration following MI. Human amniotic membrane is isolated from human placenta and engineered to be a thermoresponsive, injectable gel around body temperature. Ultrasound-guided injection of hAM matrix into rat MI hearts significantly improves cardiac contractility, as measured by ejection fraction (EF), and decrease fibrosis. The results of this study demonstrate the feasibility of engineering as an injectable hAM matrix and its efficacy in attenuating degenerative changes in cardiac function following MI, which may have broad applications in tissue regeneration.
缺血性心脏病是全球范围内主要的致死原因。心肌梗死后心力衰竭与严重的纤维化形成和心脏重构有关。最近，可注射水凝胶作为一种有前途的方法出现，可以通过微创给药来修复梗死心脏并改善心脏功能。在这里，开发了一种新型的可注射人羊膜（hAM）基质，以增强心肌梗死后的心脏再生。人羊膜从人胎盘分离出来，并被工程化为一种在体温周围具有热响应性的可注射凝胶。超声引导将 hAM 基质注射到大鼠心肌梗死心脏中，可显著改善射血分数（EF）等心脏收缩性，并减少纤维化。这项研究的结果证明了可注射 hAM 基质的工程可行性及其在减轻心肌梗死后心脏功能退行性变化方面的功效，这可能在组织再生方面具有广泛的应用。
